EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Somatic BRCA1/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high grade serous carcinoma

Robert L Hollis, Michael Churchman, Graeme R Grimes, Alison M Meynert, Philippe Gautier, Lynn McMahon, Kitty Sherwood, Ailsa J Oswald, Ian Croy, Michelle Ferguson, Cameron W Martin, Trevor McGoldrick und 10 weitere

European Journal of Cancer · 2025

DOI: 10.1016/j.ejca.2025.115299 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Robert L Hollis und 21 weiteren Autor:innen. Beteiligte Einrichtung: The Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, …. Hauptthemen laut MEDLINE: BRCA2 Protein, Ovarian Neoplasms, Germ-Line Mutation, BRCA1 Protein. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Chief Scientist Office, UK Research and Innovation Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BRCA2 ProteinOvarian NeoplasmsGerm-Line MutationBRCA1 ProteinCystadenocarcinoma, SerousMutationFallopian Tube NeoplasmsHumansFemaleMiddle AgedAgedAdultNeoplasm Grading

Stichwörter der Autor:innen

BRCA1BRCA2GermlineOvarian cancerSomatic mutationSurvival

Substanzen

BRCA2 ProteinBRCA2 protein, humanBRCA1 ProteinBRCA1 protein, human

Autor:innen und Institutionen

  • The Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK. Electronic address: robb.hollis@ed.ac.uk.
  • The Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
  • MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
  • Precision Medicine Scotland (PMS-IC), Queen Elizabeth University Hospital, Glasgow, UK.
  • MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK; Department of Oncology, University of Oxford, Oxford, UK; Edinburgh Cancer Research, Cancer Research UK Scotland Centre,…
  • Department of Oncology, NHS Tayside, Dundee, UK.

Förderung

  • Cancer Research UK
  • Chief Scientist Office
  • UK Research and Innovation Medical Research Council

Zitieren

APA

Hollis, R. L., Churchman, M., Grimes, G. R., Meynert, A. M., Gautier, P., McMahon, L., Sherwood, K., Oswald, A. J., Croy, I., Ferguson, M., Martin, C. W., McGoldrick, T., McPhail, N., Creedon, H., Barrett, J. C., March, R., Dougherty, B. A., Roxburgh, P., Ewing, A., …, & Gourley, C. (2025). Somatic BRCA1/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high grade serous carcinoma. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115299

Vancouver

Hollis RL, Churchman M, Grimes GR, Meynert AM, Gautier P, McMahon L, et al. Somatic BRCA1/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high grade serous carcinoma. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115299

BibTeX
@article{Hollis2025,
  author = {Hollis, Robert L and Churchman, Michael and Grimes, Graeme R and Meynert, Alison M and Gautier, Philippe and McMahon, Lynn and Sherwood, Kitty and Oswald, Ailsa J and Croy, Ian and Ferguson, Michelle and Martin, Cameron W and McGoldrick, Trevor and McPhail, Neil and Creedon, Helen and Barrett, J Carl and March, Ruth and Dougherty, Brian A and Roxburgh, Patricia and Ewing, Ailith and Herrington, C Simon and Semple, Colin A and Gourley, Charlie},
  title = {Somatic BRCA1/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high grade serous carcinoma},
  journal = {European Journal of Cancer},
  year = {2025},
  doi = {10.1016/j.ejca.2025.115299}
}
Kostenlos starten →